Reduce GSK Pharma; target of Rs 2118: Dolat Capital

ght86
Dolat Capital

  • Accumulate PNC Infratech; target of Rs 113: Dolat Capital

  • Accumulate Godrej Consumer; target of Rs 1605: Dolat Capital

  • Buy Zensar Tech; target of Rs 1075: Dolat Capital

Dolat Capital is bearish on GlaxoSmithKline Pharmaceuticals and has recommended reduce rating on the stock with a target of Rs 2118 in its November 9, 2011 research report.